Yahoo Web Search

Search results

1. www.fiercebiotech.com › biotech › fda-halts-juno-carFDA halts Juno CAR-T trial after three patient deaths

   www.fiercebiotech.com › biotech › fda-halts-juno-car

   • Cached

   Jul 7, 2016 · clinical trial CAR-T Clinical Data. Juno Therapeutics ($JUNO) had hoped to have a first approval for one of its candidates next year. But that looks unlikely to happen as the pivotal...

2. lymphoma.org › news › the-u-s-food-and-drugThe U.S. Food and Drug Administration Approves Lisocabtagene ...

   lymphoma.org › news › the-u-s-food-and-drug

   • Cached

   On May 30, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory mantle cell lymphoma (MCL) who have received two or more prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi).

3. classic.clinicaltrials.gov › ct2 › showA Study to Evaluate the Safety, Tolerability, Efficacy, and ...

   classic.clinicaltrials.gov › ct2 › show

   • Cached

   Jan 23, 2024 · ClinicalTrials.gov Identifier: NCT06220201. Recruitment Status : Recruiting. First Posted : January 23, 2024. Last Update Posted : May 9, 2024. See Contacts and Locations. View this study on the modernized ClinicalTrials.gov. Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Collaborator: Celgene Corporation.

   • Allocation: Non-Randomized
   • Intervention Model: Single Group Assignment

   • Estimated Enrollment : 98 participants
   • Study Type : Interventional (Clinical Trial)

4. www.geekwire.com › 2022 › junos-lasting-legacy-how-Juno's lasting legacy: How the cell therapy juggernaut ...

   www.geekwire.com › 2022 › junos-lasting-legacy-how-

   • Cached

   Feb 8, 2022 · Early clinical studies were showing dramatic rates of remissions in leukemia patients treated with their own immune cells, rewired to attack tumors. The data was exciting, but the technology...

   • 
   • 
   • 
   • 

5. www.nejm.org › doi › fullGPRC5D-Targeted CAR T Cells for Myeloma | NEJM

   www.nejm.org › doi › full

   Sep 28, 2022 · Published September 28, 2022. N Engl J Med 2022;387: 1196 - 1206. DOI: 10.1056/NEJMoa2209900. VOL. 387 NO. 13. Abstract. Background. B-cell maturation antigen (BCMA)–directed chimeric antigen...

6. news.bms.com › news › detailsBristol Myers Squibb - U.S. Food and Drug Administration ...

   news.bms.com › news › details

   • Cached

   Feb 5, 2021 · Bristol Myers Squibb - U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma.

7. www.biospace.com › article › releasesOne-Time CAR-T Leader Juno Shows Off Promising New Clinical ...

   www.biospace.com › article › releases

   • Cached

   Nov 2, 2017 · Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.